REGN - Regeneron's Triple Threat: Eylea Libtayo And Dupixent Dominate

2024-03-26 14:36:26 ET

Summary

• Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo.
• Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence.
• Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development.
• I recommend buying Regeneron shares, due to diversified product strength, pipeline potential, and manageable risks despite market challenges.

Regeneron: Sailing the Eye of the Market Storm with Eylea HD

I last covered Regeneron Pharmaceuticals, Inc. ( REGN ) in August, right after it received FDA approval for its high-dose Eylea (Eylea HD), a blockbuster drug for the treatment of wet age-related macular degeneration [AMD]. My recommendation was "buy," and the stock, up 16% since that call, is essentially even with the broader market....

For further details see: